Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) Invested Capital (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Invested Capital data on record, last reported at $196.4 million in Q3 2025.

  • For Q3 2025, Invested Capital fell 45.35% year-over-year to $196.4 million; the TTM value through Sep 2025 reached $196.4 million, down 45.35%, while the annual FY2024 figure was $312.5 million, 238.43% up from the prior year.
  • Invested Capital reached $196.4 million in Q3 2025 per ZBIO's latest filing, down from $239.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $359.4 million in Q3 2024 and bottomed at -$288.8 million in Q2 2024.
  • Average Invested Capital over 3 years is $47.0 million, with a median of $196.4 million recorded in 2025.
  • Peak YoY movement for Invested Capital: skyrocketed 277.73% in 2024, then plummeted 45.35% in 2025.
  • A 3-year view of Invested Capital shows it stood at -$225.7 million in 2023, then surged by 238.43% to $312.5 million in 2024, then crashed by 37.13% to $196.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $196.4 million in Q3 2025, $239.6 million in Q2 2025, and $284.3 million in Q1 2025.